Search Results for "data"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for data. Results 331 to 340 of 1100 total matches.

The Female Condom

   
The Medical Letter on Drugs and Therapeutics • Dec 24, 1993  (Issue 912)
COPYRIGHT LAWS CONCLUSION — The new female condom, judging from the limited data available, appears ...
A condom for women (Reality - Wisconsin Pharmacal) to prevent pregnancy and sexually transmitted diseases, including AIDS, has been approved for marketing by the US Food and Drug Administration (FDA). Already available in many family planning clinics, it will be available in pharmacies in a few months.
Med Lett Drugs Ther. 1993 Dec 24;35(912):123-4 |  Show IntroductionHide Introduction

Vinorelbine For Treatment of Advanced Non-Small-Cell Lung Cancer

   
The Medical Letter on Drugs and Therapeutics • Aug 18, 1995  (Issue 955)
% and a median survival of 40 weeks (T Le Chevalier et al, J Clin Oncol, 12:360, 1994). Preliminary data ...
Vinorelbine (Navelbine - Burroughs Wellcome), a semisynthetic vinca alkaloid, has been approved by the US Food and Drug Administration for parenteral use in the treatment of advanced non-small-cell lung cancer (NSCLC). Various combinations of cisplatin (Platinol), vinblastine (Velban, and others), mitomycin (Mutamycin), ifosfamide (Ifex), etoposide (VePesid) and paclitaxel (Taxol) have been used previously for this indication.
Med Lett Drugs Ther. 1995 Aug 18;37(955):72-3 |  Show IntroductionHide Introduction

Topotecan Hydrochloride for Metastatic Ovarian Cancer

   
The Medical Letter on Drugs and Therapeutics • Oct 25, 1996  (Issue 986)
OF U.S. AND INTERNATIONAL COPYRIGHT LAWS CONCLUSION — Although published data are limited, topotecan ...
Topotecan hydrochloride (Hycamtin - SmithKline Beecham) was recently approved by the U.S. Food and Drug Administration for parenteral use as a single agent in patients with metastatic ovarian cancer refractory to other drugs. Initial treatment for metastatic ovarian cancer usually consists of cisplatin (Platinol) or carboplatin (Paraplatin) plus paclitaxel (Taxol) or cyclophosphamide (Cytoxan, and others).
Med Lett Drugs Ther. 1996 Oct 25;38(986):96-7 |  Show IntroductionHide Introduction

Gliadel Wafers for Treatment of Brain Tumors

   
The Medical Letter on Drugs and Therapeutics • Sep 11, 1998  (Issue 1035)
implantation of the Gliadel wafers are unknown, but animal data obtained with similar polymer implants indicate ...
A biodegradable polymer 'wafer' (Gliadel - Rh ne-Poulenc Rorer) impregnated with the alkylating agent carmustine (BCNU; Bicnu) has been marketed in the USA for local treatment of recurrent glioblastoma multiforme that requires re-operation. The dime-sized polyanhydride wafers are implanted into the surgical cavity left behind after resection. Release of the alkylating agent directly into the area of the tumor bypasses the blood-brain barrier (H Brem and R Langer, Sci Med, 3:1, 1996).
Med Lett Drugs Ther. 1998 Sep 11;40(1035):92 |  Show IntroductionHide Introduction

FDA Requires Lower Dosing of Zolpidem

   
The Medical Letter on Drugs and Therapeutics • Jan 21, 2013  (Issue 1408)
is already recommended in a lower dose for women.2 New Data – Driving simulation and laboratory studies ...
On January 10, 2013, the FDA issued a news release to announce that it was requiring the manufacturers of the zolpidem-containing products Ambien, Ambien CR, Edluar and Zolpimist, which are all approved for treatment of insomnia, to lower the doses for women and to recommend in their labeling consideration of a lower dose for men. No change will be required in the dose of Intermezzo, a low-dose sublingual formulation of zolpidem for middle-of-the-night awakening, which is already recommended in a lower dose for women.
Med Lett Drugs Ther. 2013 Jan 21;55(1408):5 |  Show IntroductionHide Introduction

Turmeric Supplements

   
The Medical Letter on Drugs and Therapeutics • Nov 18, 2019  (Issue 1585)
by CYP3A.17 PREGNANCY — No data are available on the safety of turmeric use during pregnancy or while ...
Turmeric is a spice derived from the Curcuma longa plant. Dietary supplements and foods containing turmeric are widely promoted for relief of pain and to improve joint mobility, immunity, digestion, cardiovascular health, depression, anxiety, memory, and cognition.
Med Lett Drugs Ther. 2019 Nov 18;61(1585):185 |  Show IntroductionHide Introduction

Table: Over the Counter At-Home Tests for COVID-19 (online only)

   
The Medical Letter on Drugs and Therapeutics • Oct 20, 2021  (Issue 5041)
%/98% N/A = not currently commercially available; N.D. = no data available 1. Positive percent ...
View the Table: Over the Counter At-Home Tests for COVID-19
Med Lett Drugs Ther. 2021 Oct 20;63(5041):e1   doi:10.58347/tml.2021.5041a |  Show IntroductionHide Introduction

Inavolisib (Itovebi) for Locally Advanced or Metastatic Breast Cancer (online only)

   
The Medical Letter on Drugs and Therapeutics • Nov 11, 2024  (Issue 1715)
. No data are available on the presence of inavolisib in breast milk or its effects on the breastfed infant ...
Inavolisib (Itovebi – Genentech), an oral kinase inhibitor, has been approved by the FDA for use in combination with palbociclib and fulvestrant for treatment of endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer. This is the first approval for Itovebi; palbociclib and fulvestrant have been available for years for treatment of HR-positive, HER2-negative breast cancer.
Med Lett Drugs Ther. 2024 Nov 11;66(1715):e186-7   doi:10.58347/tml.2024.1715f |  Show IntroductionHide Introduction

Atorvastatin - A New Lipid-lowering Drug

   
The Medical Letter on Drugs and Therapeutics • Mar 28, 1997  (Issue 997)
Atherosclerosis Soc, 66th Congress, Florence, 1996, page 214). No data are available on the effects ...
Atorvastatin (Lipitor - Parke-Davis), an HMG-CoA reductase inhibitor (or 'statin'), was recently approved by the US Food and Drug Administration for treatment of primary hypercholesterolemia and mixed dyslipidemia. A single stereoisomer of a pyrrole derivative, the new drug is chemically different from other statins.
Med Lett Drugs Ther. 1997 Mar 28;39(997):29-31 |  Show IntroductionHide Introduction

Lasik and Its Alternatives: An Update

   
The Medical Letter on Drugs and Therapeutics • Jan 19, 2004  (Issue 1174)
), but supporting data from patients with comparable degrees of myopia and astigmatism are limited. One small study ...
Since the last Medical Letter article on surgical correction of refractive errors (Volume 41, page 122, 1999), some new techniques have been tried and new results have been reported.
Med Lett Drugs Ther. 2004 Jan 19;46(1174):5-7 |  Show IntroductionHide Introduction